Deferiprone: A Forty-Year-Old Multi-Targeting Drug with Possible Activity against COVID-19 and Diseases of Similar Symptomatology.

Abstract

The need for preparing new strategies for the design of emergency drug therapies against COVID-19 and similar diseases in the future is rather urgent, considering the high rate of morbidity and especially mortality associated with COVID-19, which so far has exceeded 18 million lives. Such strategies could be conceived by targeting the causes and also the serious toxic side effects of the diseases, as well as associated biochemical and physiological pathways. Deferiprone (L1) is an EMA- and FDA-approved drug used worldwide for the treatment of iron overload and also other conditions where there are no effective treatments. The multi-potent effects and high safety record of L1 in iron loaded and non-iron loaded categories of patients suggests that L1 could be developed as a "magic bullet" drug against COVID-19 and diseases of similar symptomatology. The mode of action of L1 includes antiviral, antimicrobial, antioxidant, anti-hypoxic and anti-ferroptotic effects, iron buffering interactions with transferrin, iron mobilizing effects from ferritin, macrophages and other cells involved in the immune response and hyperinflammation, as well as many other therapeutic interventions. Similarly, several pharmacological and other characteristics of L1, including extensive tissue distribution and low cost of production, increase the prospect of worldwide availability, as well as many other therapeutic approach strategies involving drug combinations, adjuvant therapies and disease prevention.

• Authors: George J Kontoghiorghes
• Journal: International journal of molecular sciences (Int J Mol Sci) Vol. 23 Issue 12 (Jun 16 2022) ISSN: 1422-0067 [Electronic] Switzerland
• PMID: 35743183 (Publication Type: Journal Article, Review)

Chemical References

• Iron Chelating Agents
• Pyridones
• Deferiprone
• Iron

Topics

• Adult
• Deferiprone (therapeutic use)
• Humans
• Iron (therapeutic use)
• Iron Chelating Agents (adverse effects)
• Iron Overload (chemically induced, etiology)
• Pyridones (pharmacology, therapeutic use)
• COVID-19 Drug Treatment